Expression of calpastatin, minopontin, NIPSNAP1, rabaptin-5 and neuronatin in the phenylketonuria (PKU) mouse brain: Possible role on cognitive defect seen in PKU

Neurochemistry International

Volumn 46, Issue 8, 2005, Pages 595-599

  Surendran, Sankar ^a   Tyring, Stephen K ^b   Matalon, Reuben ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b University of Texas Health Science Center at Houston   (United States)

Author keywords

BTBR Pahenu2; Calpastatin; Minopontin; Neuronatin; NIPSNAP 1; Phenylketonuria; Rabaptin 5

Indexed keywords

CALPASTATIN; MINOPONTIN; NEURONATIN; PROTEIN; RABAPTIN 5; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENYLKETONURIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; WESTERN BLOTTING; WILD TYPE;

EID: 18144373395     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2005.02.010     Document Type: Article

References (45)

1. E. Adamec, P. Mohan, J.P. Vonsattel, and R.A. Nixon Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2 Acta Neuropathol. 104 2002 92 104
2. S. Cabib, T. Pascucci, R. Ventura, V. Romano, and S. Puglisi-Allegra The behavioural profile of severe mental retardation in a genetic mouse model of phenylketonuria Behav. Genet. 33 2003 301 310
3. M.A. Cleary, J.H. Walter, J.E. Wraith, J.P. Jenkins, S.M. Alani, K. Tyler, and D. Whittle Magnetic resonance imaging of the brain in phenylketonuria Lancet 344 1994 87 90
4. T. Coppola, H. Hirling, V. Perret-Menoud, S. Gattesco, S. Catsicas, G. Joberty, I.G. Macara, and R. Regazzi Rabphilin dissociated from Rab3 promotes endocytosis through interaction with Rabaptin-5 J. Cell Sci. 114 2001 1757 1764
5. A. Diamond, and C. Herzberg Impaired sensitivity to visual contrast in children treated early and continuously for phenylketonuria Brain 119 1996 523 538
6. S. Fukuda, K. Harada, M. Kunimatsu, T. Sakabe, and K. Yoshida Postischemic reperfusion induces alpha-fodrin proteolysis by m-calpain in the synaptosome and nucleus in rat brain J. Neurochem. 70 1998 2526 2532
7. L.A. Gleason, K. Michals, R. Matalon, P. Langenberg, and S. Kamath A treatment program for adolescents with phenylketonuria Clin. Pediatr. (Phila) 31 1992 331 335
8. K. Ishimaru, N. Tamasawa, M. Baba, M. Matsunaga, and K. Takebe Phenylketonuria with adult-onset neurological manifestation Rinsho Shinkeigaku 33 1993 961 965
9. M.B. Kennedy, M.K. Bennett, and N.E. Erondu Biochemical and immunochemical evidence that the "major postsynaptic density protein" is a subunit of a calmodulin-dependent protein kinase Proc. Natl. Acad. Sci. U.S.A. 80 1983 7357 7361
10. N. Kikyo, C.M. Williamson, R.M. John, S.C. Barton, C.V. Beechey, S.T. Ball, B.M. Cattanach, M.A. Surani, and J. Peters Genetic and functional analysis of neuronatin in mice with maternal or paternal duplication of distal Chr 2 Develop. Biol. 190 1997 66 77
11. G.M. Knudsen, S. Hasselbalch, P.B. Toft, E. Christensen, O.B. Paulson, and H. Lou Blood-brain barrier transport of amino acids in healthy controls and in patients with phenylketonuria J. Inherit. Metab. Dis. 18 1995 653 664
12. W.J. Lee, H. Ma, E. Takano, H.Q. Yang, M. Hatanaka, and M. Maki Molecular diversity in amino-terminal domains of human calpastatin by exon skipping J. Biol. Chem. 267 1992 8437 8442
13. V. Leuzzi, S. Rinalduzzi, F. Chiarotti, P. Garzia, G. Trasimeni, and N. Accornero Subclinical visual impairment in phenylketonuria. A neurophysiological study (VEP-P) with clinical, biochemical, and neuroradiological (MRI) correlations J. Inherit. Metab. Dis. 21 1998 351 364
14. C. Luscher, R.A. Nicoll, R.C. Malenka, and D. Muller Synaptic plasticity and dynamic modulation of the postsynaptic membrane Nat. Neurosci. 3 2000 545 550
15. M. Maki, H. Ma, E. Takano, Y. Adachi, W.J. Lee, M. Hatanaka, and T. Murachi Calpastatins: biochemical and molecular biological studies Biomed. Biochim. Acta 50 1991 509 516
16. R. Matalon, S. Surendran, K.M. Matalon, S. Tyring, M. Quast, W. Jinga, E. Ezell, and S. Szucs Future role of large neutral amino acids in transport of phenylalanine into the brain Pediatrics 112 2003 1570 1574
17. R. Matalon, R. Koch, K. Michals-Matalon, K. Moseley, S. Surendran, S. Tyring, H. Erlandsen, A. Gamez, R.C. Stevens, A. Romstad, L.B. Moller, and F. Guttler Biopterin responsive phenylalanine hydroxylase deficiency Genet. Med. 6 2004 27 32
18. P.A. McCombe, D.B. McLaughlin, J.B. Chalk, N.N. Brown, J.J. McGill, and M.P. Pender Spasticity and white matter abnormalities in adult phenylketonuria J. Neurol. Neurosurg. Psychiatry 55 1992 359 361
19. J.D. McDonald, V.C. Bode, W.F. Dove, and A. Shedlovsky Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase Proc. Natl. Acad. Sci. U.S.A. 87 1990 1965 1967
20. H. McLauchlan, J. Newell, N. Morrice, A. Osborne, M. West, and E. Smythe A novel role for rab5-GDI in ligand sequestration into clathrin-coated pits Curr. Biol. 8 1998 34 45
21. J.D. Porter, S. Khanna, H.J. Kaminski, J.S. Rao, A.P. Merriam, C.R. Richmonds, P. Leahy, J. Li, W. Guo, and F.H. Andrade A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice Human Mol. Genet. 11 2002 263 272
22. H. Purnell Phenylketonuria and maternal phenylketonuria Breastfeed Rev. 9 2001 19 21
23. V. Rybin, O. Ullrich, M. Rubino, K. Alexandrov, I. Simon, M.C. Seabra, R. Goody, and M. Zerial GTPase activity of Rab5 acts as a timer for endocytic membrane fusion Nature 383 1996 266 269
24. T.C. Saido, H. Sorimachi, and K. Suzuki Calpain: new perspectives in molecular diversity and physiological-pathological involvement FASEB J. 8 1994 814 822
25. K. Satoh, M. Takeuchi, Y. Oda, M. Deguchi-Tawarada, Y. Sakamoto, K. Matsubara, T. Nagasu, and Y. Takai Identification of activity-regulated proteins in the postsynaptic density fraction Genes Cells 7 2002 187 197
26. R.H. Scannevin, and R.L. Huganir Postsynaptic organization and regulation of excitatory synapses Nat. Rev. Neurosci. 1 2000 133 141
27. C.R. Scriver Garrod's foresight: our hindsight J. Inherit. Metab. Dis. 24 2001 93 116
28. C.R. Scriver, and E.P. Treacy Is there treatment for "genetic" disease? Mol. Genet. Metab. 68 1999 93 102
29. C.R. Scriver, and P.J. Waters Monogenic traits are not simple: lessons from phenylketonuria Trends Genet. 15 1999 267 272
30. C.R. Scriver, M. Hurtubise, D. Konecki, M. Phommarinh, L. Prevost, H. Erlandsen, R. Stevens, P.J. Waters, S. Ryan, D. McDonald, and C. Sarkissian PAHdb 2003: what a locus-specific knowledgebase can do Human Mutat. 21 2003 333 344
31. E. Seroussi, H.Q. Pan, D. Kedra, B.A. Roe, and J.P. Dumanski Characterization of the human NIPSNAP1 gene from 22q12: a member of a novel gene family Gene 212 1998 13 20
32. A. Shedlovsky, J.D. McDonald, D. Symula, and W.F. Dove Mouse models of human phenylketonuria Genetics 134 1993 1205 1210
33. I. Smith, M.G. Beasley, and A.E. Ades Intelligence and quality of dietary treatment in phenylketonuria Arch. Dis. Child 65 1990 472 478
34. H. Sorimashi, S. Ishiura, and K. Suzuki Structure and physiological function of calpains Biochem. J. 328 1997 721 732
35. H. Stenmark, G. Vitale, O. Ullrich, and M. Zerial Rabaptin-5 is a direct effector of the small GTPase Rab5 in endocytic membrane fusion Cell 83 1995 423 432
36. Surendran, S., Matalon, R., 2004. Progress in Canavan disease. The Science Advisory Board. http://www.scienceboard.net/community/perspectives.108. html.
37. S. Surendran, K.A. Sacksteder, S.J. Gould, J.G. Coldwell, P.L. Rady, S.K. Tyring, and R. Matalon Malonyl CoA decarboxylase deficiency: C to T transition in intron 2 of the MCD gene J. Neurosci. Res. 65 2001 591 594
38. S. Surendran, G.A. Campbell, S.K. Tyring, K. Matalon, J.D. McDonald, and R. Matalon High levels of orexin A in the brain of the mouse model for phenylketonuria: possible role of orexin A in hyperactivity seen in children with PKU Neurochem. Res. 28 2003 1891 1894
39. S. Surendran, P.L. Rady, S. Szucs, K. Michals-Matalon, S.K. Tyring, and R. Matalon High level of orexin A observed in the phenylketonuria mouse brain is due to the abnormal expression of prepro-orexin Biochem. Biophys. Res. Commun. 317 2004 522 526
40. R. Surtees, and N. Blau The neurochemistry of phenylketonuria Eur. J. Pediatr. 159 2000 S109 S113
41. A.J. Thompson, S. Tillotson, I. Smith, B. Kendall, S.G. Moore, and D.P. Brenton Brain MRI changes in phenylketonuria: associations with dietary status Brain 116 1993 811 821
42. A.J. Thompson, I. Smith, D. Brenton, B.D. Youl, G. Rylance, D.C. Davidson, B. Kendall, and A.J. Lees Neurological deterioration in young adults with phenylketonuria Lancet 336 1990 602 605
43. G. Vitale, V. Rybin, S. Christoforidis, P.-E. Thornqvist, M. McCaffrey, H. Stenmark, and M. Zerial Distinct Rab-binding domains mediate the interaction of Rabaptin-5 with GTP-bound Rab4 and Rab5 EMBO J. 17 1998 1941 1951
44. J. Weglage, M. Pietsch, B. Funders, H.G. Koch, and K. Ullrich Neurological findings in early treated phenylketonuria Acta Paediatr. 84 1995 411 415
45. L. Zagreda, J. Goodman, D.P. Druin, D. McDonald, and A. Diamond Cognitive deficits in a genetic mouse model of the most common biochemical cause of human mental retardation J. Neurosci. 19 1999 6175 6182